Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

MarioNawfal

KFF Health News

MRNA Vaccine Prevented Melanoma From Returning, Drugmakers Say

The Times (UK)

Verifying Device

The Wall Street Journal

Moderna Merck Vaccine Succeeds In Preventing Melanoma From Returning 540E9E18

DrCatharineY

DrChoueiri

adamfeuerstein

ColonelTowner

Moderna shares surge as melanoma vaccine with Merck succeeds in large trial

StarPlatinum_

Ynet

Moderna, Merck mRNA melanoma vaccine succeeds in first late-stage cancer trial

STAT

Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial

BostonGlobe.com

Cancer vaccine succeeded in late-stage trial, Moderna and Merck say

Anadolu Agency

Experimental cancer vaccine shows promise in late-stage trial

CNBC

Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%

Metaculus

When will there be a breakthrough in the treatment of hard-to-treat cancers?

Merck and Moderna announced Wednesday that a personalized mRNA cancer vaccine, Intismeran, combined with Merck's immunotherapy Keytruda, met the primary goal of reducing melanoma recurrence and a secondary goal of preventing the cancer from spreading in a Phase 3 trial.

Merck and Moderna announced Wednesday that a personalized mRNA cancer vaccine, Intismeran, combined with Merck's immunotherapy Keytruda, met the primary goal of reducing melanoma recurrence and a secondary goal of preventing the cancer from spreading in a Phase 3 trial.

The Phase 3 trial enrolled 1,137 patients with high-risk stage IIB through IV melanoma whose tumors had been surgically removed. Participants were randomly assigned to receive Keytruda plus up to nine doses of the personalized vaccine, or Keytruda alone, for about one year.

The Phase 3 trial enrolled 1,137 patients with high-risk stage IIB through IV melanoma whose tumors had been surgically removed. Participants were randomly assigned to receive Keytruda plus up to nine doses of the personalized vaccine, or Keytruda alone, for about one year.

The latest results build on a mid-stage trial reported in January, in which the combination reduced the risk of melanoma recurrence or death by 49% after five years compared with Keytruda alone. The companies said no new safety concerns had emerged in the Phase 3 trial.

The latest results build on a mid-stage trial reported in January, in which the combination reduced the risk of melanoma recurrence or death by 49% after five years compared with Keytruda alone. The companies said no new safety concerns had emerged in the Phase 3 trial.

Each vaccine dose is custom-made for an individual patient based on genetic sequencing of mutations in that person's tumor, aiming to train the immune system to recognize and destroy those unique cancer markers alongside Keytruda's immune-boosting effect.

Each vaccine dose is custom-made for an individual patient based on genetic sequencing of mutations in that person's tumor, aiming to train the immune system to recognize and destroy those unique cancer markers alongside Keytruda's immune-boosting effect.

Merck and Moderna began collaborating on personalized cancer vaccines in 2016. The Phase 3 trial marks the first randomized, late-stage study to prove the benefit of so-called neoantigen vaccines as a cancer treatment.

Merck and Moderna began collaborating on personalized cancer vaccines in 2016. The Phase 3 trial marks the first randomized, late-stage study to prove the benefit of so-called neoantigen vaccines as a cancer treatment.

Moderna shares rose as much as 90% in premarket trading following the announcement, while Merck shares climbed more than 8%. According to Barclays, the vaccine could generate over $3 billion in annual melanoma sales by 2035.

Moderna shares rose as much as 90% in premarket trading following the announcement, while Merck shares climbed more than 8%. According to Barclays, the vaccine could generate over $3 billion in annual melanoma sales by 2035.

NBC #

KFF Health News #

The Times (UK) #

The Wall Street Journal #

CNN #

Ynet #

STAT #

BostonGlobe.com #

Anadolu Agency #

CNBC #

Metaculus #

The Phase 3 trial enrolled 1,137 patients with high-risk stage IIB through IV melanoma whose tumors had been surgically removed. Participants were randomly assigned to receive Keytruda plus up to nine doses of the personalized vaccine or Keytruda alone for approximately one year.

The Phase 3 trial enrolled 1,137 patients with high-risk stage IIB through IV melanoma whose tumors had been surgically removed. Participants were randomly assigned to receive Keytruda plus up to nine doses of the personalized vaccine or Keytruda alone for approximately one year.

Each vaccine dose is custom-made for an individual patient based on genetic sequencing of mutations found in that person's tumor, with the goal of training the immune system to recognize and destroy those unique cancer markers alongside Keytruda's immune-boosting effect.

Each vaccine dose is custom-made for an individual patient based on genetic sequencing of mutations found in that person's tumor, with the goal of training the immune system to recognize and destroy those unique cancer markers alongside Keytruda's immune-boosting effect.

Merck and Moderna began collaborating on personalized cancer vaccines in 2016. The Phase 3 trial marks the first randomized late-stage study aimed at definitively proving the benefit of so-called neoantigen vaccines as a cancer treatment.

Merck and Moderna began collaborating on personalized cancer vaccines in 2016. The Phase 3 trial marks the first randomized late-stage study aimed at definitively proving the benefit of so-called neoantigen vaccines as a cancer treatment.

Moderna shares rose as much as 90% in premarket trading following the announcement, while Merck shares climbed more than 8%. Analysts have estimated an approved product could generate over $3 billion in annual melanoma sales by 2035.

Moderna shares rose as much as 90% in premarket trading following the announcement, while Merck shares climbed more than 8%. Analysts have estimated an approved product could generate over $3 billion in annual melanoma sales by 2035.

Moderna's mRNA cancer vaccine is just the latest chapter in a troubling pattern — the same controversial technology behind COVID shots that triggered myocarditis warnings and global political firestorms is now being repackaged as a cancer cure. The stock pumping 90% on Phase 3 news smells more like financial engineering than a medical miracle. Trust in mRNA was shattered once, and rushing to rebuild it on the back of cancer patients is a dangerous gamble.

Moderna's mRNA cancer vaccine is just the latest chapter in a troubling pattern — the same controversial technology behind COVID shots that triggered myocarditis warnings and global political firestorms is now being repackaged as a cancer cure. The stock pumping 90% on Phase 3 news smells more like financial engineering than a medical miracle. Trust in mRNA was shattered once, and rushing to rebuild it on the back of cancer patients is a dangerous gamble.

ColonelTowner-Watkins

StarPlatinum

The first positive Phase 3 trial of a personalized mRNA cancer vaccine is a genuine landmark — this isn't hype, it's hard clinical evidence from over 1,100 patients showing real reductions in recurrence for high-risk melanoma. Designing a treatment around each tumor's unique mutations was once a dream, and now it's reality. 2026 deserves to be remembered as the year mRNA technology proved its most consequential promise had nothing to do with COVID.

The first positive Phase 3 trial of a personalized mRNA cancer vaccine is a genuine landmark — this isn't hype, it's hard clinical evidence from over 1,100 patients showing real reductions in recurrence for high-risk melanoma. Designing a treatment around each tumor's unique mutations was once a dream, and now it's reality. 2026 deserves to be remembered as the year mRNA technology proved its most consequential promise had nothing to do with COVID.

Dr. Catharine Young

Toni Choueiri, MD

Adam Feuerstein

In Covid’s Wake: How Our Politics Failed Us

Gain-of-Function Research and the COVID Origins Debate

mRNA Melanoma Vaccine Succeeds in Phase 3 Trial

mRNA Melanoma Vaccine Succeeds in Phase 3 Trial

Health

Pharmaceuticals

The first positive Phase 3 trial of a personalized mRNA cancer vaccine is a genuine landmark — not hype, but hard clinical evidence from over 1,100 patients showing real reductions in recurrence for high-risk melanoma. Designing a treatment around each tumor's unique mutations was once a dream, and now it's reality. 2026 deserves to be remembered as the year mRNA technology proved its most consequential promise had nothing to do with COVID.

The first positive Phase 3 trial of a personalized mRNA cancer vaccine is a genuine landmark — not hype, but hard clinical evidence from over 1,100 patients showing real reductions in recurrence for high-risk melanoma. Designing a treatment around each tumor's unique mutations was once a dream, and now it's reality. 2026 deserves to be remembered as the year mRNA technology proved its most consequential promise had nothing to do with COVID.

There's a 50% chance that there will be a breakthrough in the treatment of hard-to-treat cancers by Oct. 29, 2030, according to the Metaculus prediction community.

There's a 50% chance that there will be a breakthrough in the treatment of hard-to-treat cancers by Oct. 29, 2030, according to the Metaculus prediction community.

mRNA Cancer Vaccine Succeeds in Late-Stage Melanoma Trial

mRNA MelanomaCancer Vaccine Succeeds in PhaseLate-Stage 3Melanoma Trial

The Spin

Metaculus Prediction

Go Deeper